Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
The enzyme encoded by GLO1 is responsible for the catalysis and formation of S-lactoyl-glutathione from methylglyoxal condensation and reduced glutatione. Additionally we are shipping Glyoxalase I Proteins (21) and Glyoxalase I Kits (13) and many more products for this protein.
Showing 10 out of 78 products:
Human Polyclonal GLO1 Primary Antibody for EIA, WB - ABIN453056
Germanová, Germanová, Tesarová, Jáchymová, Zvára, Zima, Kalousová: Glyoxalase I Glu111Ala polymorphism in patients with breast cancer. in Cancer investigation 2009
Show all 2 references for ABIN453056
Human Polyclonal GLO1 Primary Antibody for ELISA, WB - ABIN561054
Sato, Kwon, Kamisuki, Srivastava, Mao, Kawazoe, Uesugi: Polyproline-rod approach to isolating protein targets of bioactive small molecules: isolation of a new target of indomethacin. in Journal of the American Chemical Society 2007
Show all 2 references for ABIN561054
Crystal structure of the mouse Glo1-inhibitor complex was determined at 2.3 A resolution.
Study demonstrates that GLO1 is a novel metabolic oncogene (show RAB1A Antibodies) of the 6p21 amplicon, which promotes tumor growth and aberrant transcriptional signals via regulating cellular metabolic activities for energy production.
the balance between methylglyoxal and age-dependent GLO1 downregulation contributes to delayed wound healing in old mice
The difference in glyoxalase-1 mRNA was observed with Fkbp5 (show FKBP5 Antibodies)-/- mice expressing 2-fold more glyoxylase-1 protein.
pharmacological inhibition of GLO1 reduced anxiety, suggesting that GLO1 is a possible target for the treatment of anxiety disorders.
These results suggest that GLO-1 plays a role in high glucose-mediated signaling by reducing mesangial cells accumulation and oxidative stress in diabetes mellitus.
Findings reveal that the abundance of GLO1 varies between different murine strains and within different sensory neuron populations.
Data show that reducing RGS2 (show RGS2 Antibodies) expression by antisense treatment prevented the increase in GLO1 and GSR1 (show GSR Antibodies) mRNA and protein expression.
Data demonstrate GLO1 expression and glycation damage to be induced by alpha-synuclein (show SNCA Antibodies) ablation leading to the suggestion that wild-type alpha-synuclein (show SNCA Antibodies) modulates brain glucose metabolism.
Glo-I is a novel molecular target for treatment of Bcr-Abl (show ABL1 Antibodies)(+) leukemias, and Abl (show ABL1 Antibodies) TKI-resistant quiescent Bcr-Abl (show ABL1 Antibodies)(+) leukemic cells that have acquired stem-like characteristics in the process of adapting to a hypoxic environment.
Studies indicate that the most extensively investigated The most extensively investigated glyoxalase enzymes are glyoxalase I and glyoxalase II (show HAGH Antibodies) (Glo1 and Glo2 (show HAGH Antibodies)).
The GLO1 variations were not the source of association of the BTBD9 (show BTBD9 Antibodies) locus with restless legs syndrome.
Glo1 is involved in the Min-U-Sil (show PMEL Antibodies) 5 crystalline silica-induced BEAS-2B cell mitochondrial apoptotic pathway.
GLO1 activity affects the overall burden of carotid artery atherosclerosis.
individuals with the GLO1 A /E genotype, PON192/QR-RR genotypes and PON55/LM-MM genotypes had a significantly higher risk of cerebral cavernous malformations compared with the other genotypes.
This study demonstrated that the GLO1 C332 (Ala111) allele confers autism vulnerability by reducing brain glyoxalase activity and enhancing advanced glycation end-products. formation
This review describes the role of GLO1 in tumor cell proliferation and survival, and the potential of GLO1 as a biomarker for tumor diagnosis and as a target for anticancer drug development. [review]
Significant differences in the allelic and genotype frequencies of GLO1.
In ApoE (show APOE Antibodies)(-/-) mice with or without diabetes, GLO1 overexpression did not lead to decreased atherosclerotic lesion size or systemic inflammation.
Data show that GlxI is a novel substrate of TG2 (show TGM2 Antibodies) and TG2 (show TGM2 Antibodies) catalyzes either polyamine conjugation or deamidation depending the presence of polyamines.
The enzyme encoded by this gene is responsible for the catalysis and formation of S-lactoyl-glutathione from methylglyoxal condensation and reduced glutatione. Glyoxalase I is linked to HLA and is localized to 6p21.3-p21.1, between HLA and the centromere.
, glyoxalase I
, hypothetical protein
, trypanothione-dependent glyoxalase I
, S-D-lactoylglutathione methylglyoxal lyase
, glx I
, glyoxalase 1 complex
, glyoxalase 1 regulatory
, glyoxalase 1 structural
, ketone-aldehyde mutase
, glyoxylase 1
, glyoxalase domain containing 1
, lactoyl glutathione lyase